Search results
A description of these risks and uncertainties can be found in Pfizer’s most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form ...
- Financial Reports Quarterly Reports and More
Financial Reports Quarterly Reports and More - Pfizer Inc. -...
- SEC Filings
SEC Filings - Pfizer Inc. - Investor Relations - Financials...
- Overview
Overview - Pfizer Inc. - Investor Relations - Financials -...
- Covid-19 Vaccine Distributing Hope to The World
Every detail down to packaging size mattered. For the global...
- Covid-19 Vaccine Rollout New Digital Technologies
Pfizer and BioNTech’s embrace of novel mRNA science played a...
- Board Committees & Charters
Board Committees & Charters - Pfizer Inc. - Investor...
- Corporate Governance FAQs
Corporate Governance FAQs - Pfizer Inc. - Investor Relations...
- Why Invest
Why Invest - Pfizer Inc. - Investor Relations - Financials -...
- Financial Reports Quarterly Reports and More
Pfizer Chairman and CEO Albert Bourla summarizes company performance and achievements in 2023 and previews what’s to come as we celebrate 175 years of changing patients’ lives.
This page contains information about Pfizer's scientific breakthroughs for patients across multiple therapeutic areas in 2022, spotlights on noteworthy Pfizer colleagues and Bold Moves update charting how Pfizer is progressing toward its purpose of breakthroughs that change patients' lives.
MOST RECENT 2023 Annual Report and Form 10K. View PDF View Form 10K (HTML) Pfizer Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
2002 Pfizer (PFE) 10-K Annual Report - Mar 28th, 2002 375kb. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022
This page contains information about Pfizer's scientific breakthroughs for patients across multiple therapeutic areas in 2021, spotlights on noteworthy Pfizer colleagues and Bold Moves update charting how Pfizer is progressing toward its purpose of breakthroughs that change patients' lives.
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-3619 PFIZER INC.
